The next generation of single domain antibodies
Emglev Therapeutics
A unique synthetic single domain antibodies company dedicated to discover and develop transformative immunotherapies.
Cancer is the second most common cause of death worldwide, with over 10 million deaths per year. Solid tumors represent 90% of new cancer diagnoses, but some forms do not respond to conventional therapies and represent a challenge for medicine.
New therapeutic approaches, based on monoclonal antibodies and CAR-T, help only a small fraction of patients. There is a real need to develop innovative Ac-based approaches for solid tumors.
New therapeutic approaches, based on monoclonal antibodies and CAR-T, help only a small fraction of patients. There is a real need to develop innovative Ac-based approaches for solid tumors.
Cancer is the second most common cause of death worldwide, with over 10 million deaths per year. Solid tumors represent 90% of new cancer diagnoses, but some forms do not respond to conventional therapies and represent a challenge for medicine. New therapeutic approaches, based on monoclonal antibodies and CAR-T, help only a small fraction of patients. There is a real need to develop innovative Ac-based approaches for solid tumors.
Emglev
Therapeutics
Therapeutics
A unique synthetic single domain antibodies company dedicated to discover and develop transformative immunotherapies.
Mission
Established in 2023 as a spin-off of Institut Curie, Emglev is dedicated to the discovery and the development of next generation immunotherapies to address conditions with high unmet medical needs in oncology.
Vision
We aim at unlocking the next level of immunotherapies by discovering treatments for the benefit of the patients with high unmet needs in several indications such as the treatment of solid tumors and other pathologies.
Pipeline
Driven by therapeutic need, we are currently developing a diversified pipeline focused on the treatment of solid tumors. Ultimately, through partnerships, we will extend our therapeutic arsenal to a wide range of indications with significant medical needs to reach more patients.
Approach
Leveraging our unique proprietary platform, expertise and innovative approach, we unlock the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target.
Team with a strong and complementary expertise
Pipeline of proprietary sdAbs-based therapies
Unique full-stack discovery engine
Worldwide
recognition
The development of the NaLi-H1 phage-displayed library is probably one of the most comprehensive and detailed studies focused on the design and validation of a synthetic Nb library.
Our Partners
France's leading cancer center, which brings together 3,700 researchers, doctors and caregivers around its three missions: Care, Research and Teaching.
A community of entrepreneurs united to bring their innovations to market for the benefit of patients and healthcare professionals.
Bpifrance is a French public investment bank, dedicated to financing and developing businesses.
As the 1st winner of the France 2030 NextGenerationEU program, the Paris Saclay Cancer Cluster is changing the pace of innovation in oncology to make it more predictive, precise and efficient.
Want to be part of the evolution?
© Copyright 2023 Emglev Therapeutics. All rights reserved